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Summary
This report presents CDC’s recommended case definitions and surveillance practices for Acute Idiopathic Pulmonary Hemor-
rhage (AIPH). In 1994 and 1997, CDC reported clusters of acute pulmonary hemorrhage (APH) among infants in Cleveland,
Ohio. Subsequent reviews of these investigations identified shortcomings in the conduct of the studies and concluded that the
investigations did not prove an association between APH among infants and exposure to molds. In response to recommendations
from these reviews, with assistance of external consultants, CDC staff developed a plan to conduct surveillance for and investiga-
tion of AIPH. In developing this response, CDC recommends a definition for a clinically confirmed case of AIPH among infants
on the basis of evidence of blood in the airway, age <1 year, absence of medical conditions related to pulmonary hemorrhage, and
severe acute respiratory distress or respiratory failure. CDC recommends that pediatric intensive care units (PICUs) report cases
that meet the CDC case definition to state health departments. CDC staff will study the number of reported cases of AIPH among
infants and also review the Cleveland and Chicago case series to determine the degree to which the present case definition applies
to them. If these reviews establish that AIPH among infants is a public health problem, on the basis of its magnitude or geographic
or temporal distribution, targeted case surveillance will be initiated based on the distribution of cases. CDC staff will work with
state and local health departments to investigate reported clusters of cases of AIPH among infants.
Background
This report presents CDC’s recommendations for case defi-
nitions for Acute Idiopathic Pulmonary Hemorrhage (AIPH)
among infants and CDC’s plan for retrospective surveillance
for AIPH among infants, including a study to evaluate the
feasibility of using International Classification of Diseases (ICD)
(1) codes for surveillance for AIPH.
In 1994 and 1997, CDC reported clusters of acute pulmo-
nary hemorrhage (APH) among infants (2,3) in Cleveland,
Ohio. During 1992–1994, a similar cluster occurred in the
Chicago area (4). In Cleveland, risk factors for illness included
male sex; lack of breast-feeding; residence in households with
smokers; residence in homes where water damage had occurred
during the previous 6 months; and residence in homes with
increased quantities of fungi, including Stachybotrys atra.
Reviews by CDC staff and external consultants of these
investigations identified shortcomings in the conduct of the
studies (5). These panels concluded that the investigations did
not prove an association between APH among infants and
exposure to molds, specifically S. chartarum (atra). These
reviewers recommended that CDC, pediatric pulmonologists,
and state and local public health officials collaborate to
• develop a standard surveillance case definition;
• develop standard protocols for data collection and envi-
ronmental assessment;
• implement surveillance for AIPH;
• investigate cases of AIPH among infants, particularly when
clusters are identified, considering associations with mul-
tiple possible etiologies; and
• enhance sampling and laboratory analytic methods to
improve assessment of environmental exposures to molds
and fungi (5).
In response to the reviewers’ recommendations, CDC staff
developed a plan to conduct surveillance for AIPH, investi-
gate clusters of cases, and conduct studies. In formulating this
response, CDC convened three meetings to establish a case
definition and classification scheme for public health surveil-
lance for AIPH, recommend a standard home environmental
investigation protocol, and outline a plan for surveillance and
investigation of AIPH among infants. As a consequence of
these meetings, CDC has determined that a series of surveil-
lance activities should be initiated to direct future efforts. In
addition to providing an overview of the results of the three
meetings, this report describes surveillance activities and how
results from those activities can guide efforts to investigate
the burden and etiology of AIPH among infants.
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AIPH among infants is a diagnosis of exclusion. Certain
syndromes (Box 1) and other disease states can occur with
pulmonary hemorrhage. Thus, differential diagnoses and neo-
natal medical problems that can cause pulmonary hemorrhage
should be ruled out.
Meeting Panelists and Goals
Three meetings of panelists were convened to advise CDC
staff regarding investigation of AIPH among infants. The Case
Definition Panel included three pediatric pulmonologists, one
pediatric intensive care specialist, one pediatric pathologist,
two epidemiologists, and one environmental epidemiologist.
The purpose of this panel was to recommend a case definition
for use in public health surveillance for AIPH to facilitate case
finding. Case finding will facilitate documentation of the bur-
den of the condition and identification of possible etiologic
agents or risk factors.
The Surveillance Implementation Panel included one
pediatrician, one pediatric pulmonologist, one forensic
pathologist, three epidemiologists (including one state epide-
miologist), and four environmental epidemiologists (includ-
ing one state epidemiologist and one toxicologist). Its purpose
was to recommend a standard approach for public health sur-
veillance for AIPH.
The Home/Indoor Environment and Laboratory Investi-
gation Panel included two mycologists, one biochemist, two
microbiologists, two industrial hygienists, two toxicologists,
and one environmental epidemiologist. Its purpose was to rec-
ommend standard approaches and protocols for environmen-
tal data collection, laboratory analysis, and data interpretation
during public health surveillance for AIPH.
For each of the three areas, group discussion led by a mod-
erator was based on prepared questions. Participants produced
written summaries, which form the basis of the recommenda-
tions provided in this report.
BOX 1. Pulmonary hemorrhage terminology
The term used for the cluster of cases reported in Cleve-
land* was pediatric idiopathic pulmonary hemorrhage and
hemosiderosis. The term pulmonary hemorrhage has been
used to describe situations with identifiable causes of bleed-
ing.† Idiopathic pulmonary hemosiderosis (IPH)§ or pri-
mary hemosiderosis¶ has been used to denote presumably
idiopathic bleeds or the accumulation of iron as hemosid-
erin.§ The terms pulmonary hemorrhage and primary
hemosiderosis are often used interchangeably.** The new
International Classification of Diseases, Tenth Revision (ICD-
10) mortality coding system†† has no code for idiopathic
pulmonary hemosiderosis. The CDC definition of a case
of AIPH in an infant uses the term pulmonary hemosid-
erosis as a pathological finding to denote the possible
occurrence of pulmonary hemorrhage, and not to describe
a clinical syndrome.
The term pulmonary hemorrhage encompasses multiple
clinical syndromes, including
• diffuse pulmonary hemorrhage;§§
• pulmonary hemorrhage of the newborn (ICD-9: 770.3;
ICD-10: P26)¶¶ or hemoptysis;
• cough with hemorrhage;
• pulmonary hemorrhage not otherwise specified (ICD-9:
786.3; ICD-10 R04, R04.2); and
• idiopathic pulmonary hemosiderosis (ICD-9: 516.1, no
ICD-10 code).
Sources:
* Montana E, Etzel RA, Allan T, Horgan TE, Dearborn DG. Environmental risk factors associated with pediatric idiopathic pulmonary hemorrhage/hemosiderosis
in a Cleveland community. Pediatrics 1997;99:117.
† Heiner DC. Pulmonary hemosiderosis. In: Chernick V, Kendig EL Jr, eds. Disorders of the respiratory tract in Children. 5th ed. Philadelphia, PA: W.B.
Saunders, 1990:498–509. Langston C, Askin FB. Pulmonary disorders in the neonate, infant, and child. In: Thurlbeck WM, Churg AM, eds. Pathology of
the lung. 2nd ed. New York, NY: Thieme Medical Publishers, 1995:151–94.
§ Firth JR, McGeady SJ, Smith DS. Pulmonary hemosiderosis. In: Chernick V, Kendig EL Jr, eds. Disorders of the respiratory tract in children. 5th ed.
Philadelphia, PA: W.B. Saunders, 1990:966–76.
¶ Hay JG, Turner-Warwick M. Pulmonary hemosiderosis, hemorrhagic syndromes and other rare infiltrative disorders. In: Murray JF, Nadel JA, eds. Textbook
of respiratory medicine. Philadelphia, PA: W.B. Saunders, 1988:1501–5.
** Boat TF. Pulmonary hemorrhage and hemoptysis. In: Chernick V, Boat TF, Kendig E, eds. Kendig’s disorders of the respiratory tract in children. 6th ed.
Philadelphia, PA: W.B. Saunders, 1998:623–33.
†† World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva, Switzerland: World Health
Organization, 1992.
§§ Hay JG, Turner-Warwick M. Pulmonary hemosiderosis, hemorrhagic syndromes and other rare infiltrative disorders. In: Murray JF, Nadel JA, eds. Textbook
of respiratory medicine. Philadelphia, PA: W.B. Saunders, 1988:1501–5. CDC. Availability of case definition for acute idiopathic pulmonary hemorrhage in
infants [Notice to readers]. MMWR 2001;50:494–5. Schwarz MI, Cherniack RM, King TE. Diffuse alveolar hemorrhage and other rare infiltrative disorders.
In: Murray JF, Nadel JA, eds. Textbook of respiratory medicine 3rd ed. Philadelphia, PA: W.B. Saunders, 2000:1733–55.
¶¶ Schwarz MI, Cherniack RM, King TE Jr. Diffuse alveolar hemorrhage and other rare infiltrative disorders. In: Murray JF, Nadel JA, eds. Textbook of
respiratory medicine 2nd ed. Philadelphia, PA: W.B. Saunders, 1994:1889–912. Cutz E. Idiopathic pulmonary hemosiderosis and related disorders in infancy
and childhood. Perspect Pediatr Pathol 1987;11:47–81. Miller RR: Diffuse pulmonary hemorrhage. In: Thurlbeck WM, Churg AM, eds. Pathology of the
lung. 2nd ed. New York, NY: Thieme Medical Publishers, 1995:365–73. Castile R, Kleinberg F. Pathogenesis and management of massive pulmonary
hemorrhage in the neonate: case report of a normal survivor. Mayo Clin Proc 1976;51:155–8.
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Case Definition
Case Classification and Severity
Criteria
AIPH is the sudden onset of pulmonary hemorrhage in a
previously healthy infant in whom differential diagnoses and
neonatal medical problems that might cause pulmonary hem-
orrhage have been ruled out. Pulmonary hemorrhage can
appear as hemoptysis or blood in the nose or airway with no
evidence of upper respiratory or gastrointestinal bleeding.
Patients have acute, severe respiratory distress or failure,
requiring mechanical ventilation and chest radiograph (CXR),
and usually demonstrate bilateral infiltrates.
AIPH among infants and sudden infant death syndrome
(SIDS) potentially share similar risk factors (e.g., age group
and maternal cigarette smoking). Also, in certain cases, SIDS
is associated with pulmonary hemorrhage found at autopsy
(6,7). Thus, factors that are known risk factors for SIDS should
be identified when evaluating an infant possibly having AIPH.
Potential information sources for case-identification and case-
status classification during an investigation of pulmonary hem-
orrhage are provided (Table 1).
Clinically Confirmed Cases of AIPH
Among Infants
Criteria for a confirmed case include pulmonary hemor-
rhage in a previously healthy infant aged <1 year with a gesta-
tional age of >32 weeks, with no history of neonatal medical
problems that might cause pulmonary hemorrhage, and whose
condition meets all of the following three criteria:
• Abrupt or sudden onset of overt bleeding or obvious evi-
dence of blood in the airway, including
— epistaxis, hemoptysis, or frank blood in the airway
below the larynx at visualization, not caused by any
medical procedure (e.g., laryngoscopy or intubation);
or
— identification of hemosiderin-laden macrophages
(>20% of pulmonary macrophages containing hemo-
siderin on bronchoalveolar lavage or biopsy specimen).
A source of bleeding from the nose and oropharynx
should be ruled out at the time of admission.
• Severe-appearing illness leading to acute respiratory dis-
tress or respiratory failure, resulting in hospitalization in
a pediatric intensive care unit (PICU) or neonatal inten-
sive care unit (NICU) with intubation and mechanical
ventilation.
• Diffuse unilateral or bilateral pulmonary infiltrates vis-
ible on CXR or computerized tomography (CT) of the
chest. CXR or chest CT findings should be documented
within 48 hours of examination of the infant.
A previously healthy infant should
• have been discharged from the hospital after birth with
an uneventful course before the occurrence of
bronchoalveolar hemorrhage;
• never have been previously intubated, nor required respi-
ratory support with oxygen;
TABLE 1. Information sources for infant acute idiopathic pulmonary hemorrhage case identification and case-status classification
Potential data source
Health-care admission notes from
house officer, attending physician,
nurses, or social worker
Chest radiograph or chest computer-
ized tomography (CT)
Hematology laboratory
Fiber-optic bronchoscopy or blind





• Notations of physical abuse, sudden infant death syndrome, or history of smoking in the home
• Presence of infiltrates on pre- versus postintubation chest radiograph or CT
• Hemoglobin; hematocrit; red cell indices; white cell count and differential; or arterial blood gas
• If unavailable, original recording of oxygen saturation by oximetry, before supplemental oxygen was
administered, or the first oximetry and recorded oxygen flow
• Coagulation profile
• Percentage hemosiderin-laden macrophages
— If >20%, hemorrhage >48 hours before examination is indicated
— If <20%, bleeding might have been <48 hours before examination
• Percentage of lipid-laden macrophages
• Cultures include viral, bacterial, and fungal (silver stain)
• Cell differential
• Milk precipitins
• Immunoglobulins (e.g., IgG and subclasses)
• Guaiac
* Infant should be stable enough to tolerate the procedure during the first 48 hours of mechanical support. Perform to guide diagnosis and therapy† for
unstable patients with a life-threatening event based on clinical judgment (Source: Jean-Baptiste E. Clinical assessment and management of massive
hemoptysis. Crit Care Med 2000;28:1642–7).
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• not have evidence of physical abuse;
• not have any abnormality identified on admission or
follow-up bronchoscopy that would explain the bleed-
ing; and
• not have neonatal medical problems that can cause pul-
monary hemorrhage.
CDC will adhere closely to this case definition, requiring
that all the criteria be met for a confirmed case. The defini-
tion for a clinically confirmed case excludes pulmonary hem-
orrhage among older children and infants with restricted access
to a PICU. Because no criteria exist for postmortem examina-
tions, this definition excludes infants who die before hospital
and PICU admission, whose illness might have met the case
definition. However, the definitions for probable and suspect
cases (see the following) will capture the majority of these
cases and allow identification of illness among infants who
die before examination by a physician.
Probable Cases of AIPH Among Infants
Criteria for a probable case include a previously healthy
infant aged <1 year with a gestational age of >32 weeks,
• who has a sudden onset of bleeding from the airway, with
or without respiratory distress, with or without intuba-
tion, and with or without pulmonary infiltrates on CXR
or chest CT;
or
• who died and had evidence of bleeding from the airway
found on autopsy or postmortem; had been in respira-
tory distress; would or should have been intubated in the
opinion of a clinician; and would have had infiltrates on
CXR or chest CT.
Suspected Cases of AIPH Among Infants
Criteria for a suspected case include a previously healthy
infant,
• who died and had evidence of bleeding from the airway
found on autopsy or postmortem or who
• either did not have chest imaging studies or had imaging
studies that indicated no pulmonary infiltrates.
Respiratory distress or intubation is not required for a sus-
pected case.
Severity Classification Scheme for AIPH
Among Infants
Because of the potential for variation in symptoms among
infants for each of the criteria, different case combinations
might be related to the timing or duration of symptoms, dis-
ease severity, pathologic processes, or etiologic agents associ-
ated with AIPH among infants. A discussion of the proposed
case-classification categories for AIPH among infants is pro-
vided (Tables 2 and 3).
something yet to learn."
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a. First criterion met
b. First criterion met
a. Infant died; diagnosis of bleeding based
on autopsy or postmortem findings
b. Infant died; diagnosis of bleeding based
on autopsy or postmortem findings
c. First criterion met
a. First criterion met
b. First criterion met
a. Infant died; diagnosis of bleeding based
on autopsy or postmortem findings
b. First criterion met
a. Infant died; diagnosis of bleeding based
on autopsy or postmortem findings
b. Infant died; diagnosis of bleeding based
on autopsy or postmortem findings
Second criterion
Intubated; acute respiratory
distress or respiratory failure
Second criterion met
Second criterion met
In PICU§ with severe respiratory
distress, but not intubated
Not in severe respiratory distress
In PICU with severe respiratory
distress, but not intubated
Would have been intubated in the
opinion of the clinician
Would have been intubated in the
opinion of the clinician
Second criterion met
In PICU with severe respiratory
distress, but not intubated
Not in severe respiratory distress
Not in severe respiratory distress
Not in severe respiratory distress
Would have been intubated in the
opinion of the clinician
















No pulmonary infiltrates; no CXR/CT
No pulmonary infiltrates; no CXR/CT
* Rankings of 1–5 represent categories with decreasing levels of certainty; 1 = highly probable, and 5 = least probable. The letter designations, a, b, and c
represent approximately equivalent levels within each criterion.
†CXR = chest radiograph; CT = computerized tomography.
§PICU = pediatric intensive care unit.




Probable, 2a or 2b
Probable, 3a, 3b, 5a, or suspected
Discussion
• Bleeding might begin in a localized region of one lung with dispersion of blood to other areas of the lung
through the airways
• Initial chest radiograph (CXR) might indicate unilateral infiltrates, but following dispersion indicates diffuse
infiltrates
• Infants with unilateral infiltrates are considered confirmed for AIPH, but their characteristics might be
different from infants with diffuse infiltrates
• Not considered confirmed because identification depends on lavage or biopsy finding of hemosiderin-laden
macrophages and not on active bleeding or recovering blood from below the larynx
• Work of breathing might vary for infants with a similar pathology (e.g., resulting from different body
temperature, serum glucose levels, and duration of respiratory distress)
• Infants who do not need intubation would not have acute bleeding directly identified from below the glottis
• Upon initial examination, infants’ circumstances might vary; information should be collected to identify these
circumstances as best as possible during data abstraction so that the categories can be expanded if
needed during data analysis
• The circumstances might be that 1) the attending physician intended to intubate an infant who died; 2) the
clinician who reviewed the death of an infant with postmortem findings consistent with pulmonary hemor-
rhage secondary to clinical respiratory failure thought the infant should have been intubated; 3) the infant
died before arrival at the hospital and therefore was not intubated nor received thoracic imaging studies
• Age-specific normochromic, normocytic, or microangiopathic anemia might indicate different pathophysi-
ologic processes and in conjunction with appropriate clinical signs and symptoms might be supportive of a
diagnosis of AIPH
* Rankings of 1–5 represent categories with decreasing levels of certainty; 1 = highly probable, and 5 = least probable. The letter designations a, b, and
c represent approximately equivalent levels within each category (see also Table 2).
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A summary of clinical features of AIPH among infants
(Table 4) (Box 2) and neonatal medical problems and differ-
ential diagnoses that should be ruled out before classifying a
case as AIPH among infants (Box 3) are included. Other dif-
ferential diagnoses associated with pulmonary hemorrhage are
listed (Table 5).
Feasibility Study To Determine
the Concordance of ICD Codes
for Pulmonary Hemorrhage
with the CDC Case Definition
Prospective nationwide surveillance for cases of AIPH among
infants is difficult to justify on the basis of the available epide-
miologic data. In addition to the limitations reported for the
Cleveland study (5), no risk factors were conclusively linked
to disease in the Chicago investigation (4), and only one other
cluster (in Detroit) was reported during 1992–1996 (7).
CDC will retrospectively review cases of pulmonary hem-
orrhage to determine the public health impact of AIPH among
infants and to generate hypotheses regarding the importance
of risk factors possibly associated with AIPH among infants.
If that review indicates that AIPH among infants is a separate
clinical entity and that these cases have occurred in clusters,
or that an increase in incidence or mortality is associated with
these cases, CDC will initiate prospective surveillance and case
ascertainment to identify cases for epidemiologic studies
designed to confirm or disprove associations between pulmo-
nary hemorrhage host factors, environmental factors, and bio-
logic agents, including such molds as S. chartarum (5).
Retrospective Review by Using Existing
Data Sources
The ability to use existing data sources should substantially
facilitate both determining the public health impact of AIPH
among infants. However, the reliable data regarding mortality
from pulmonary hemorrhage is only available at the national
level. CDC conducted a preliminary evaluation of ICD codes
for surveillance of pulmonary hemorrhage among infants to
determine whether existing data sources can be used to esti-
mate the magnitude of the problem of AIPH among infants.
CDC examined data from the National Hospital Discharge
Survey (NHDS) and National Mortality Data. Possible cases of
AIPH among infants were identified by using ICD-9 codes
770.3, 784.7, 784.8, 786.3, and 516.1 (Table 6).
Infants identified by ICD-9 codes 770.3 and 786.3 differ
from the cases reported in Cleveland. In the national datasets,
the majority of cases of pulmonary hemorrhage had diagnoses
such as prematurity or immaturity and death occurring within
the first 7 days of life. The Cleveland cases occurred among
stable, healthy, mature infants who had been discharged from
the hospital to their homes after birth and subsequently expe-
rienced pulmonary hemorrhage (8–10). Thus, the estimates
of deaths and hospital admissions for cases of pulmonary hem-
orrhage using ICD codes 770.3 and 786.3 does not distinctly
identify infants with AIPH as defined by CDC. In addition,
these national datasets do not determine if infants had identi-
fiable etiologies or complications before their discharge from
the hospital or their death. Because the estimated number of
hospitalized cases with a primary diagnosis of pulmonary hem-
orrhage was less than the number of deaths, these national
datasets might not be reliable for surveillance for infantile
pulmonary hemorrhage. These analyses might be better per-
formed by using state-based data.
A retrospective review for AIPH among infants will be per-
formed in metropolitan cities in those states with the highest
death rates and with >100 deaths associated with pulmonary
hemorrhage among infants, on the basis of relevant ICD-9
and ICD-10 codes used from 1979 to the most recent avail-
able data. By focusing on PICUs and NICUs with substantial
numbers of deaths, cases from innercity catchment areas, where
the incidence of AIPH among infants is suspected to be higher,
will be captured. Potential cases will be identified by using
standardized methods of case ascertainment and data collec-
tion from hospital discharge and mortality data sources, based
on ICD codes. Potential cases will be compared with the rec-
ommended case definition by reviewing medical records
related to all cases of pulmonary hemorrhage observed since
1979 among children aged <2 years.
This retrospective review of AIPH among infants will
• determine whether AIPH among infants is a distinct clini-
cal entity within existing ICD-9/ICD-10 diagnostic codes
for pulmonary hemorrhage;
• describe the epidemiology of pulmonary hemorrhage;
• identify trends in the frequency of cases and the geographic
distribution and clustering of cases;
• estimate the public health impact of AIPH among infants;
• identify groups at high risk for AIPH among infants; and
• determine the need for prospective surveillance as a source
of cases for a case-control study.
The data will be reviewed to determine how these cases,
including the apparent case clusters of AIPH among infants
in Cleveland and Chicago, have been coded on hospital dis-
charge abstracts, and how deaths attributed to the syndrome
have been characterized on death certificates. Both Ohio and
Illinois meet the criteria of >100 deaths from pulmonary hem-
orrhage. In Cleveland and Chicago, this review also will
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TABLE 4. Clinical features of acute idiopathic pulmonary hemorrhage (AIPH) among infants
Finding
No evidence of cow milk protein allergy or associated respiratory, heart, kidney, or pancreatic disease*
Abrupt cessation of crying or unusual crying or irritability hours to days before the initial recognition of
blood in the airway†
Not observed§
Decreased muscle tone and dusky pallor minutes to hours before progressing to sudden onset of
hypoxemic respiratory distress or failure¶
Hours to days before onset of respiratory failure**
Accompanies or immediately precedes respiratory failure††
Acute and appears to be idiopathic§§
Characterized by tachypnea, grunting, and chest retractions¶¶
Diffusely diminished breath sounds without the presence of rales or rhonchi***
Often requires intubation and mechanical ventilation; intubation when required is for 2–7 days†††
Often demonstrates bilateral pulmonary infiltrates within the first 24 hours§§§
Typically, alveolar infiltrates begin to clear within the first 24–48 hours¶¶¶
Atraumatic intubation; bronchoscopy including inspection of upper airway****
Typically, no source from the lung or gastrointestinal tract; presumed to be from diffuse alveolar capillary
injury††††
Typically, found in bronchoalveolar lavage fluid; might not be present in an infant experiencing an acute,
initial pulmonary bleed§§§§
Indicates evidence of bleeding into the lungs; finding >20% of total pulmonary macrophages containing
hemosiderin can be consistent with pulmonary hemorrhage that occurred >48 hours before examination¶¶¶¶
First 48 hours, fragmented or damaged red blood cells, hemoglobinuria; microangiopathic anemia might
be indicative of a hemolytic process; normochromic normocytic might be consistent with acute, abrupt
blood loss*****
Serum negative for antiglomerular basement membrane antibody, anticytoplasmic neutrophilic antibody,
complement titers, serum immune complexes, and antinuclear antibody†††††
None; spontaneous recovery with or without supportive care indicates these pathophysiologic processes
are not the cause of bleeding
Typically normal§§§§§
Sign or symptom





Hemoptysis with or without epistaxis
Pulmonary hemorrhage
Respiratory distress
Signs of pulmonary hemorrhage
Respiratory support
First chest radiograph (CXR)
Follow-up CXR
Visualization of pulmonary hemorrhage




Vasculitis or vascular malformation
Platelet count, prothrombin time, and partial
prothrombin time
* Sources: 1) Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 2) Miller RR: Pulmonary disease in the
immunocompromised host. In: Thurlbeck WM, Churg AM, eds. Pathology of the lung. 2nd ed. New York, NY: Thieme Medical Publishers, 1995;349–64.
3) Dearborn D, Yike I, Sorenson WG, Miller MJ, Etzel RA. Overview of investigations into pulmonary hemorrhage among infants in Cleveland, Ohio.
Environ Health Perspect 1999;107(Suppl 3):495–9. 4) Etzel R, Montana E, Sorenson W, Kullman G, et al. Acute pulmonary hemorrhage among
infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 1998;152:757–62.
† Sources: 1) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3.
2) Dearborn, D. Clinical profile of thirty infants with idiopathic pulmonary hemorrhage in Cleveland (Unpublished manuscript). 3) Epstein CE, Elidemir
O, Colasurdo GN, Fan LL. Time course of hemosiderin production by alveolar macrophages in a murine model. Chest 2001;120:2013–20.
§ Sources: 1) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3.
2) Pappas M, Sarnaik AP, Meert K, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary hemorrhage in infancy. Chest 1996;110:553–5.
¶ Sources: 1) Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 2) Dearborn D, Yike I, Sorenson WG, Miller MJ, Etzel
RA. Overview of investigations into pulmonary hemorrhage among infants in Cleveland, Ohio. Environ Health Perspect 1999;107(Suppl 3):495–9. 3)
CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3. 4) Dearborn,
D. Clinical profile of thirty infants with idiopathic pulmonary hemorrhage in Cleveland (Unpublished manuscript). 5) Dearborn, D. Pulmonary hemorrhage
among infants and children. Curr Opin Pediatry 1997;9:219–24.
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** Sources: 1) Dearborn D, Yike I, Sorenson WG, Miller MJ, Etzel RA. Overview of investigations into pulmonary hemorrhage among infants in Cleveland,
Ohio. Environ Health Perspect 1999;107(Suppl 3):495–9. 2) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January
1993–November 1994. MMWR 1994;43:881–3. 3) Dearborn, D. Clinical profile of thirty infants with idiopathic pulmonary hemorrhage in Cleveland
(Unpublished manuscript). 4) Dearborn, D. Pulmonary hemorrhage among infants and children. Curr Opin Pediatry 1997;9:219–24.
†† Sources: 1) Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 2) Etzel R, Montana E, Sorenson W, Kullman G, et al.
Acute pulmonary hemorrhage among infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 1998;152:757–
62. 3) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3. 4)
Dearborn, D. Pulmonary hemorrhage among infants and children. Curr Opin Pediatry 1997;9:219–24. 5) CDC. Acute pulmonary hemorrhage among
infants Chicago, April 1992–November 1994. MMWR 1995;44:67–74. 6) Flappan S, Protnoy J, Jones P, Barnes C. Infant pulmonary hemorrhage in a
suburban home with water damage and mold (Stachybotrys atra). Environ Health Perspect 1999;107:927–30. 7) Novotny W, Dixit A. Pulmonary
hemorrhage in an infant following 2 weeks of fungal exposure. Arch Pediatr Adolesc Med 2000;154:271–5.
§§ Primary diagnostic criteria.
¶¶ Sources: 1) Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 2) CDC. Acute pulmonary hemorrhage/hemosiderosis
among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3.
*** Source: Etzel R, Montana E, Sorenson W, Kullman G, et al. Acute pulmonary hemorrhage among infants associated with exposure to Stachybotrys
atra and other fungi. Arch Pediatr Adolesc Med 1998;152:757–62.
††† Sources: 1) Etzel R, Montana E, Sorenson W, Kullman G, et al. Acute pulmonary hemorrhage among infants associated with exposure to Stachybotrys
atra and other fungi. Arch Pediatr Adolesc Med 1998;152:757–62. 2) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland,
January 1993–November 1994. MMWR 1994;43:881–3. 3) Pappas M, Sarnaik AP, Meert K, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary hemorrhage
in infancy. Chest 1996;110:553–5. 4) Flappan S, Protnoy J, Jones P, Barnes C. Infant pulmonary hemorrhage in a suburban home with water damage
and mold (Stachybotrys atra). Environ Health Perspect 1999;107:927–30. 5) Novotny W, Dixit A. Pulmonary hemorrhage in an infant following 2 weeks
of fungal exposure. Arch Pediatr Adolesc Med 2000;154:271–5.
§§§ Sources: 1) Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 2) Etzel R, Montana E, Sorenson W, Kullman G, et al.
Acute pulmonary hemorrhage among infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 1998;152:757–
62. 3) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3. 4)
De Lassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C. Alveolar hemorrhage. Diagnostic criteria and results in 194
immunocompromised hosts. Am J Respir Crit Care Med 1995;151:157–63.
¶¶¶ Sources: 1) Etzel R, Montana E, Sorenson W, Kullman G, et al. Acute pulmonary hemorrhage among infants associated with exposure to Stachybotrys
atra and other fungi. Arch Pediatr Adolesc Med 1998;152:757–62. 2) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland,
January 1993–November 1994. MMWR 1994;43:881–3. 3) Pappas M, Sarnaik AP, Meert K, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary hemorrhage
in infancy. Chest 1996;110:553–5. 4) Flappan S, Protnoy J, Jones P, Barnes C. Infant pulmonary hemorrhage in a suburban home with water damage
and mold (Stachybotrys atra). Environ Health Perspect 1999;107:927–30. 5) Novotny W, Dixit A. Pulmonary hemorrhage in an infant following 2 weeks
of fungal exposure. Arch Pediatr Adolesc Med 2000;154:271–5.
**** Sources: 1) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3.
2) Pappas M, Sarnaik AP, Meert K, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary hemorrhage in infancy. Chest 1996;110:553–5.
†††† Sources: 1) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3.
2) Pappas M, Sarnaik AP, Meert K, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary hemorrhage in infancy. Chest 1996;110:553–5.
§§§§ Sources: 1) Dearborn D, Yike I, Sorenson WG, Miller MJ, Etzel RA. Overview of investigations into pulmonary hemorrhage among infants in Cleveland,
Ohio. Environ Health Perspect 1999;107(Suppl 3):495–9. 2) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January
1993–November 1994. MMWR 1994;43:881–3. 3) Dearborn, D. Clinical profile of thirty infants with idiopathic pulmonary hemorrhage in Cleveland
(Unpublished manuscript). 4) Pappas M, Sarnaik AP, Meert K, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary hemorrhage in infancy. Chest 1996;110:553–
5. 5) Sherman JM, Winnie G, Thomassen MJ, Abdul-Karim FW, Boat TF. Time course of hemosiderin production and clearance by human pulmonary
macrophages. Chest 1984;86:409–11.
¶¶¶¶ Sources: 1) Epstein CE, Elidemir O, Colasurdo GN, Fan LL. Time course of hemosiderin production by alveolar macrophages in a murine model.
Chest 2001;120:2013–20. 2) Novotny W, Dixit A. Pulmonary hemorrhage in an infant following 2 weeks of fungal exposure. Arch Pediatr Adolesc Med
2000;154:271–5. 3) Coffin CM, Schechtman K, Cole FS, Dehner L. Neonatal and infantile pulmonary hemorrhage: an autopsy study with clinical
correlation. Pediatr Pathol 1993;13:583–9. 4) Perez-Arellano J, Losa Garcia JE, Garcia Macias MC, Gomez Gomez F, Jimenez Lopez A, de Castro S.
Hemosiderin-laden macrophages in bronchoalveolar lavage fluid. Acta Cytol 1992;36:26–30.
***** Sources: 1) Etzel R, Montana E, Sorenson W, Kullman G, et al. Acute pulmonary hemorrhage among infants associated with exposure to Stachybotrys
atra and other fungi. Arch Pediatr Adolesc Med 1998;152:757–62. 2) Pappas M, Sarnaik AP, Meert K, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary
hemorrhage in infancy. Chest 1996;110:553–5.
††††† Sources: 1) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3.
2) Pappas M, Sarnaik AP, Meert K, Hasan RA, Lieh-Lai MW. Idiopathic pulmonary hemorrhage in infancy. Chest 1996;110:553–5.
§§§§§ Sources: 1) Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 2) Etzel R, Montana E, Sorenson W, Kullman G, et al.
Acute pulmonary hemorrhage among infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 1998;152:757–
62. 3) CDC. Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993–November 1994. MMWR 1994;43:881–3.
TABLE 4. (Continued) Clinical features of acute idiopathic pulmonary hemorrhage (AIPH) among infants
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BOX 2. Clinical descriptions of pulmonary hemorrhage
In early texts, pulmonary hemorrhage was not commonly
described in children, although it was noted to occur.* Blood
found in the airways or alveoli of humans can result from
different anatomic sites. Specific sites can include alveoli,
large or small conducting airways, or the nasopharynx and
gastrointestinal tract with pulmonary aspiration. Regard-
less of the origin of blood entering the lung, substantial
amounts of blood lead to impaired gas exchange, altered
pulmonary mechanics, and respiratory distress. Different
pathophysiologic processes are associated with pulmonary
hemorrhage. These can be divided into
• conditions where bleeding occurs at sites of normal tissue
with mechanical disruption causing a loss of vascular integ-
rity (e.g., intentional suffocation and mitral valve disease);
• vascular inflammation, whereby the inflammatory pro-
cess causes a loss of vascular integrity (e.g., vasculitis sec-
ondary to such conditions as collagen vascular diseases);
• vascular malformations, whereby a combination of altered
vascular integrity and physical influences (e.g., Laplace’s
law†) lead to disruption of the blood vessel; and
• coagulopathies, which usually also require additional
physical disruption of the blood vessel through greater
than normal transpulmonary vascular pressures.
The manifestations of pulmonary hemorrhage can be clas-
sified into different syndromes. Diffuse pulmonary hem-
orrhage is usually diagnosed by bronchoscopy, either by
virtue of grossly bloody lavage fluid or by the presence of
hemosiderin-laden macrophages in bronchoalveolar lavage.
In biopsy and autopsy tissue, the diagnosis is made on the
basis of the presence of recent blood and hemosiderin in
the alveolar spaces or the interstitium.§ In the immuno-
compromised host, intra-alveolar bleeding can result from
thrombocytopenia often associated with other factors. Dif-
fuse pulmonary hemorrhage (DPH) can either be second-
ary to other disease states, associated with other organ
dysfunction, or be isolated. Isolated causes of DPH include
lung immaturity, cow milk hypersensitivity, pulmonary cap-
illary hemangiomatosis, and idiopathic causes.¶
Pulmonary hemorrhage of the newborn (ICD-9: 770.3;
ICD-10: P26) is manifested by focal hemorrhage into air-
spaces or the interstitium in the lungs of infants with
hyaline membrane disease, bronchopulmonary dysplasia,
and other neonatal pulmonary disorders.** These infants
are most often male, preterm, small for gestational age, and
have a history of perinatal stress.†† The etiology and patho-
genesis of the disorder has not been elucidated.
Hemoptysis, cough with hemorrhage, pulmonary hem-
orrhage not otherwise specified (ICD-9: 786.3; ICD-10
R04, R04.2) is an acute manifestation of bleeding from the
airway. This ICD category captures all the nonneonatal (and
certain neonatal) diagnoses of pulmonary hemorrhage.
Children with pulmonary hemorrhage might not appear
to have hemoptysis if they swallow their sputum.
Consensus is lacking on the meaning of the term idio-
pathic pulmonary hemosiderosis (ICD-9: 516.1, no ICD-
10 code). One pathology text states that the term denotes a
separate clinical entity of which diffuse pulmonary hemor-
rhage is the major manifestation.§§ A later edition of the
same text¶¶ notes that the presence of hemosiderin in lung
macrophages indicates degradation products of hemoglobin.
Hemosiderin is thus a pathologic state indicative of bleeding
of any type into the lungs*** secondary to the processing of
hemoglobin in the red blood cells in the airway by alveolar
macrophages.††† Adults with active alveolar hemorrhage have
high hemosiderin scores in bronchoalveolar lavage fluid,§§§
but hemosiderin-containing macrophages have limited dif-
ferential diagnostic value.¶¶¶ In one clinical text, the term
means diffuse recurrent intrapulmonary hemorrhage that is
not secondary to bleeding from trauma, bleeding from the
airways, tumors, or left ventricular failure.**** Another
author†††† describes variants of primary and secondary pul-
monary hemosiderosis.
On review of National Hospital Discharge Survey data
for 1979–1996 and national mortality data for 1979–1998
for ICD-9 code 516.1 for infants, no instances were found
in either dataset where ICD-9 code 516.1 was the primary
listed diagnosis. However, in 207 cases, this code was the
other listed diagnosis. This indicates that idiopathic pul-
monary hemorrhage is usually an accompanying diagnosis
to other diagnoses that result in hospitalization or death
among infants.
* Sources: 1) Heiner D. Pulmonary hemosiderosis. In: Chernick V, Kendig E., eds. Disorders of the respiratory tract in children. 5th ed. Philadelphia, PA:
W.B. Saunders, 1990:498–509. 2) Langston C, Askin FB: Pulmonary disorders in the neonate, infant, and child. In: Thurlbeck WM, Churg AM, eds.
Pathology of the lung. 2nd ed. New York, NY: Thieme Medical Publishers, 1995:151–94.
† Laplace’s law describes the relation between the transmural pressure difference (ÄP), wall tension (T), and diameter (D) related to the surface tension in a
concave surface (e.g., inside a blood vessel); ÄP = 4T/D.
§ Sources: 1) CDC. Availability of case definition for acute idiopathic pulmonary hemorrhage among infants [Notice to readers]. MMWR 2001;50:494–5.
2) Schwarz MI, Cherniack RM, King TE. Diffuse alveolar hemorrhage and other rare infiltrative disorders. In: Murray JF, Nadel JA, eds. Textbook of
respiratory medicine. 3rd ed. Philadelphia, PA: W.B. Saunders 2000:1733–55.
¶ Source: Boat TF. Pulmonary hemorrhage and hemoptysis. In: Chernick V, Boat TF, Kendig E, eds. Kendig’s disorders of the respiratory tract in children. 6th
ed. Philadelphia, PA: W.B. Saunders, 1998:623–33.
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determine the positive predictive value (PPV) between the clus-
ters of pulmonary hemorrhage cases previously reported and
the CDC definition of AIPH among infants. Because the
relation between IPH, pulmonary hemorrhage, and AIPH
among infants is not clearly understood in terms of rate, eti-
ology, and risk factors, this analysis will define basic demo-
graphics of cases among infants and whether the proposed
case definition for AIPH among infants is clearly distinguish-
able from other conditions. The magnitude and dimensions
of AIPH among infants will be determined by describing the
distribution of cases on the basis of ICD codes and the CDC
case definition. This will involve enumerating cases, deter-
mining hospital discharge and mortality rates, and describing
the distributions for available demographic variables (e.g., tem-
poral and urban versus rural differences), if any.
Investigation of Suspected Clusters
of AIPH Among Infants
If an apparent cluster of cases of pulmonary hemorrhage
occurs, CDC recommends that state health departments ini-
tiate an investigation. CDC staff will work with each state, upon
request, to evaluate case reports to assist the epidemiologic and
environmental investigation, if any. State health departments
can use existing protocols for outbreak or cluster investigations
and collect information to determine if cases meet the CDC
case definition for AIPH among infants. Because these cases
probably will be identified in PICUs, CDC recommends that
if PICU staff identify any suspected cases, they report them to
their state epidemiologist.
For each case of AIPH in an infant, CDC recommends that
PICU and NICU staff collect clinical information to certify
case status, demographic information, and reports regarding
the status of the patient’s home. PICU and NICU staff also
should carefully document illnesses that are similar clinically
to AIPH, even if another specific etiology is confirmed,
because they might offer additional information or indicate
the need to re-assess the case definition.




• Chronic lung disease
• Congenital mitral stenosis
• Cor triatriatum, pulmonary
• Hemolytic diseases affecting the newborn
• Hyaline membrane disease
• Instrumentation of the nasopharynx or airway
• Intubation
• Left-to-right cardiac shunts
• Left-sided obstructive cardiac lesions disease
• Mechanical ventilation
• Nasogastric feeding tubes
• Persistent pulmonary hypertension of the newborn
• Respiratory distress syndrome
• Surfactant administration
• Venoocclusive disorders
** Sources: 1) Castile R and Kleinberg F. Pathogenesis and management of massive pulmonary hemorrhage in the neonate. Mayo Clin Proc 1976;51:155–8.
2) Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 3) Coffin C, Schechtman K, Cole F, Dehner L. Neonatal and infantile
pulmonary hemorrhage: an autopsy study with clinical correlation. Pediatr Pulmonol 1993;13:583–9.
†† Sources: 1) Langston C, Askin FB: Pulmonary disorders in the neonate, infant, and child. In: Thurlbeck WM, Churg AM, eds. Pathology of the lung. 2nd ed.
New York, NY: Thieme Medical Publishers, 1995:151–94. 2) Castile R and Kleinberg F. Pathogenesis and management of massive pulmonary hemorrhage in
the neonate. Mayo Clin Proc 1976;51:155–8. 3) Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 4) Coffin C, Schechtman
K, Cole F, Dehner L. Neonatal and infantile pulmonary hemorrhage: an autopsy study with clinical correlation. Pediatr Pulmonol 1993;13:583–9.
§§ Source: Miller RR. Diffuse pulmonary hemorrhage. In: Thurlbeck WM, Churg AM, eds. Pathology of the lung. 2nd ed. New York, NY: Thieme Medical
Publishers, 1995: 365–73.
¶¶ Source: Miller RR: Pulmonary disease in the immunocompromised host. In: Thurlbeck WM, Churg AM, eds. Pathology of the lung. 2nd ed. New York,
NY: Thieme Medical Publishers, 1995:349–64.
*** Sources: 1) Boat TF. Pulmonary hemorrhage and hemoptysis. In: Chernick V, Boat TF, Kendig E, eds. Kendig’s disorders of the respiratory tract in children.
6th ed. Philadelphia, PA: W.B. Saunders, 1998:623–33. 2) Miller RR. Diffuse pulmonary hemorrhage. In: Thurlbeck WM, Churg AM, eds. Pathology of
the lung. 2nd ed. New York, NY: Thieme Medical Publishers, 1995: 365–73. 3) Miller RR: Pulmonary disease in the immunocompromised host. In:
Thurlbeck WM, Churg AM, eds. Pathology of the lung. 2nd ed. New York, NY: Thieme Medical Publishers, 1995:349–64.
††† Sources: 1) Sherman JM, Winnie G, Thomassen MJ, Abdul-Karim FW, Boat TF. Time course of hemosiderin production and clearance by human
pulmonary macrophages. Chest 1984;86:409–11. 2) Richter GW. Iron-loaded cell—the pathology of iron storage. Am J Pathol 1978;91:361–406. 3)
Wixom RL, Prutkin L, Munro HN. Hemosiderin: nature, formation, and significance. Internat Rev Exp Path 1980;22:193–225.
§§§ Source: Grebski E, Hess T, Georg H, Speich R, Erich R. Diagnostic value of hemosiderin-containing macrophages in bronchoalveolar lavage. Chest
1992;102:1794–99.
¶¶¶ Source: Richter GW. Iron-loaded cell—the pathology of iron storage. Am J Pathol 1978;91:361–406.
**** Source: Hay JH, Turner-Warwick M. Pulmonary hemosiderosis, hemorrhagic conditions and other rare infiltrative disorders. In: Murray JF, Nadel JA, eds.
Textbook of respiratory medicine. Philadelphia, PA: W.B. Saunders, 1988:1501–5.
†††† Source: Levy J, Wilmott RW. Pulmonary hemosiderosis. Pediatr Pulmonol 1986;2:384–91. 4) Coffin C, Schechtman K, Cole F, Dehner L. Neonatal and
infantile pulmonary hemorrhage: an autopsy study with clinical correlation. Pediatr Pulmonol 1993;13:583–9.
BOX 2. (Continued) Clinical descriptions of pulmonary hemorrhage
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If performed, environmental assessment of the home to
gather pertinent risk-assessment data should use standard pro-
tocols designed by trained environmental health profession-
als. At a minimum, the assessment should involve visual
inspection, including checks for dampness, water damage,
obvious mold, evidence of pests, and environmental tobacco
smoke. Depending on the assessed need for further evalua-
tion and the resources available, additional investigation might
include determining moisture content, settled dust sampling,
air sampling for different allergens, and biologically active
compounds, and other investigations as needed.
Conclusion
CDC recommends a definition for a clinically confirmed case
of AIPH among infants on the basis of 1) evidence of blood in
the airway; 2.) age <1 year; 3) absence of medical conditions
related to pulmonary hemorrhage; and 4) severe acute respira-
tory distress or respiratory failure, requiring admission to a PICU
with intubation and mechanical ventilation. CDC recommends
that PICUs report cases that meet the CDC case definition to
state health departments and to CDC.
CDC will retrospectively analyze state-level mortality and
hospitalization data based on ICD codes and will retrospec-










Evidence of physical abuse†





• Congenital or acquired lung disorders
• Premature lung disease
• Primary ciliary dyskinesia
• Bronchiectasis
• Cystic fibrosis
• Chronic aspiration or gastroesophageal reflux with airway soiling
• Diffuse alveolar injury (e.g., caused by caustic inhalation, toxins, radiation, pharmacologic drugs, or insecticides)
• Pulmonary hypertension
• Congenital heart disease with increased right-sided blood flow
• Myocarditis
• Pulmonary vascular congestion
• Mitral stenosis
• Congestive heart failure
• Veno-occlusive disorders
• Thrombocytopenia
• Congenital or acquired coagulopathies; bleeding disorders (e.g., hemophilia or Von Willebrand disease);
transient vitamin K deficiency, which can be caused by using anticonvulsant drugs during pregnancy, failure to
give vitamin K at birth, antibiotic use by the infant, exclusive breast feeding by the mother, and use of anticonvul-
sant drugs or herbal teas while breast feeding
• Diffuse intravascular coagulopathy
• Hemangiomas; vasculitis (rare among infants) (e.g., Henoch Schonlein purpura)
• Celiac disease
• Nephritis
—  With immune complexes (e.g., Goodpasture syndrome)
—  Without immune complexes
• Lung and systemic infections
• Wegener’s granulomatosis
• Tuberous sclerosis
• Lymphangiomyomatosis or lymphangioleiomyomatosis
• Pulmonary-renal syndrome
• Systemic lupus erythematosis
* Factors not covered in the inclusion and exclusion criteria for acute idiopathic pulmonary hemorrhage that are known risk factors for SIDS should be
identified — race, low birthweight, prematurity, co-sleeping, or type of bedding.
†Unexplained or repeated injuries (e.g., welts, bruises, or burns); injuries in the shape of an object (e.g., belt buckle or electric cord); injuries not likely to
happen given the age or ability of the child (e.g., broken bones in a child too young to walk or climb).
§From parental or guardian history or injuries that are possible given the age or ability of the child.
¶ Rare among infants.
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TABLE 6. Number of infants with primary and other listed
diagnosis of pulmonary hemorrhage — National Hospital




Type of diagnosis 770.3 786.3 Total
NHDS data, 1979–1996
Primary listed diagnosis 1,041 342 1,383
Any listed diagnosis 11,801 3,485 15,286
NMD data, 1979–1997
Primary listed diagnosis 2,685 46 2,731
* Using codes from the International Classifications of Diseases, 9th revision
(Source: World Health Organization. International classification of diseases.
9th rev. Clinical modification [ICD-9-CM]. Geneva, Switzerland: World Health
Organization, 1978.)
tively review discharges for pulmonary hemorrhage in selected
PICUs. These studies will
• distinguish between the clinical findings associated with
different symptoms of AIPH among infants;
• determine whether ICD codes capture cases that meet
the CDC-recommended case definition for AIPH among
infants;
• determine whether AIPH among infants is a distinct rec-
ognizable clinical entity;
• determine the proportion of cases ascertained retrospec-
tively through ICD-9 codes that meet the clinical case
definition by estimating PPV of ICD-coded data; and
• define the magnitude of AIPH among infants and the
need for conducting etiologic studies.
CDC will review the Cleveland and Chicago case series to
determine the degree to which the present case definition
applies to them. In addition, CDC will evaluate the present
case definition on the basis of data from initial surveillance
findings and modify it as appropriate.
If these reviews establish that AIPH among infants is a pub-
lic health problem on the basis of increasing numbers or clus-
ters of cases geographically or temporally, targeted prospective
case surveillance will be initiated. If prospective surveillance
is initiated, CDC will maintain a database of current cases of
AIPH among infants, reported by PICUs that meet the case
definition. The database will serve as a source of cases for case-
control studies to determine etiology. CDC will work with
state and local health departments to investigate clusters of
AIPH among infants cases.
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